0001104659-21-026929.txt : 20210223 0001104659-21-026929.hdr.sgml : 20210223 20210223184831 ACCESSION NUMBER: 0001104659-21-026929 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210219 FILED AS OF DATE: 20210223 DATE AS OF CHANGE: 20210223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GEMAYEL GEORGES CENTRAL INDEX KEY: 0001256088 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 21667524 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 4 1 tm217706-4_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-02-19 0 0001356576 SUPERNUS PHARMACEUTICALS, INC. SUPN 0001256088 GEMAYEL GEORGES C/O SUPERNUS PHARMACEUTICALS, INC. 9715 KEY WEST AVENUE ROCKVILLE MD 20850 1 0 0 0 Common Stock 5211 D Director Stock Option (Right to Buy) 29.61 2021-02-19 4 A 0 7365 0 A 2022-02-19 2031-02-19 Common Stock 7365 7365 D Restricted Stock Units 2021-02-19 4 A 0 4222 0 A Common Stock 4222 4222 D Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022. Exhibit 24 - Power of Attorney /s/ James P. Kelly, as attorney-in-fact 2021-02-23 EX-24 2 tm217706d4_ex24.htm EXHIBIT 24

Exhibit 24

Power of Attorney

Know all by these presents, that the undersigned hereby constitutes and appoints JACK KHATTAR and JAMES KELLY, and each of them individually, with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of Supernus Pharmaceuticals, Inc. (the “Company”), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any securities exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and condition as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in- fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS THEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of November, 2020.

	/s/ Georges Gemayel
	Georges Gemayel